Smiter
New member
Right, that's how I saw it, too. IMO, that methodology seems flawed to me because the moment we give the real drug to a group, how can they be called placebo group after that? Also, doesn't that defeat the whole purpose of a placebo group in the first place? IMO, if we want to test the efficacy of a drug over long-slow-titration, quick-dose-escalation, and a real placebo group, shouldn't we keep a third group who never gets the drug? Do you get my assertion?woundcarping said:For the ones that started getting Reta at 80 weeks, they were in the control group before that. Picture it as consecutive trials with the control groups running concurrently for the placebo and lower dose escalation trials


